CRPC with Bone Metastases: From the Editor

12 March 2018

How many times has a patient with advanced prostate cancer said to you, “I have bone cancer?” 

In the past, I would smile politely and correct them by saying, “actually what you have is prostate cancer that has spread to your bones.” But, what if they are right? I mean, many of these patients have previously undergone a prostatectomy or radiation therapy, and have no evidence of local disease. Sure, the patient may have an elevated prostate-specific antigen (PSA) level, but does that alone really make this prostate cancer? 

12 September 2017

Our ability to offer a multitude of effective therapies for the advanced prostate cancer patient continues forward, enhancing patient outcomes while minimizing quality of life untoward effects. Radium 223 (Xofigo), approved in May 2013, is the most recently approved and efficacious advanced prostate cancer (PCa) treatment, receiving level one guidelines endorsements from AUA, EAU, ASCO, ESMO, and NCCN. This addition of CRPC Bone Metastases: Center of Excellence, highlights 3 important publications, each with novel information which supports the clinician responsible for advanced PCa patients with bone metastases burden, the predominant site of metastatic location with well documented meta-analyses for advanced PCa patients worldwide. 

30 June 2017

Welcome to the Center of Excellence on Castration Resistant Prostate Cancer (CRPC) with Bone Metastases. I am Dr. Neal Shore, MD, FACS, CPI, Director of the Carolina Urologic Research Center (CURC), Atlantic Urology Clinics, Myrtle Beach, South Carolina. Founded in 1998, CURC is currently supported by 13 Urologists, 3 Radiation Oncologists, 1 Pathologist, 10 Advanced Practice Providers, and a team of 10 fulltime research and administrative CURC personnel.

23 June 2017

Coming soon